RecruitingNCT03144648

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study


Sponsor

International Agency for Research on Cancer

Enrollment

3,000 participants

Start Date

Oct 12, 2012

Study Type

OBSERVATIONAL

Conditions

Summary

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival. To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study). PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following: 1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols 2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes 3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes. 4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer. The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 45 Years

Inclusion Criteria5

  • woman between 20 and 45 years old
  • woman less than 3 years older or younger than the case
  • living in the area that the study is taking place during the past 3 years
  • woman menstruated at least once in the past 12 months
  • woman diagnosed with a primary breast cancer by histopathological examination (only for cases)

Exclusion Criteria7

  • woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers)
  • woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol)
  • woman suffering from chronic kidney failure
  • woman having a pathology that will hinder adequate communication
  • woman who is pregnant or nursing
  • woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers)
  • any other reason to exclude

Interventions

OTHERlifestyle

Observational study


Locations(13)

Barretos Cancer Hospital

Barretos, Brazil

INC

Santiago, Independencia, Chile

Hso-Crsco

Santiago, Peñalolén, Chile

FALP

Santiago, Providencia, Chile

Grupo Infección y Cáncer. Universidad de Antioquia

Medellín, Antioquia, Colombia

International Hospital of Colombia

Bucaramanga, Bucaramanga, Colombia

Facultad de Medicina, Universidad del Norte

Barranquilla, Colombia

Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia

Bucaramanga, Colombia

SENOSAMA foundation

Bucaramanga, Colombia

Instituto de Oncología HematoOncologos

Cali, Colombia

Public Health University of Narino

Pasto, Colombia

Agencia Costarricense de Investigaciones Biomédicas (ACIB)

San José, Provincia de San José, Costa Rica

Instituto Nacional de Salud Pública (INSP)

Cuernavaca, Morelos, Mexico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03144648


Related Trials